title: Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
abstract: Central post-stroke pain (CPSP), a potential sequela of stroke, is classified as neuropathic pain. Although we recently established a CPSP-like model in mice, the effects of adjuvant analgesics as therapeutic drugs for neuropathic pain in this model are unknown. Hence, the aim of the present study was to assess the usefulness of our model by evaluating the effects of adjuvant analgesics used for treating neuropathic pain in this mouse model of CPSP. Male ddY mice were subjected to 30 min of bilateral carotid artery occlusion (BCAO). The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test. The mechanical allodynia was significantly increased on day 3 after BCAO compared with that during the pre-BCAO assessment. BCAO-induced mechanical allodynia was significantly decreased by intraperitoneal injections of imipramine (a tricyclic antidepressant), mexiletine (an antiarrhythmic), gabapentin (an antiepileptic), or a subcutaneous injection of morphine (an opioid receptor agonist) compared with that following vehicle treatment in BCAO-mice. By contrast, milnacipran (a serotonin and norepinephrine reuptake inhibitor), paroxetine (selective serotonin reuptake inhibitor), carbamazepine (antiepileptic), and indomethacin (nonsteroidal anti-inflammatory drug) did not affect the BCAO-induced mechanical allodynia. Our results show that BCAO in mice may be useful as an animal model of CPSP. In addition, BCAO-induced mechanical allodynia may be suppressed by some adjuvant analgesics used to treat neuropathic pain.
authors.affiliation: Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University.
authors.forename: Wataru
authors.initials: W
authors.lastname: Matsuura
authors.forename: Shinichi
authors.initials: S
authors.lastname: Harada
authors.forename: Shogo
authors.initials: S
authors.lastname: Tokuyama
mesh_terms: D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications*; D002220:Carbamazepine / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003521:Cyclopropanes / Q000627:therapeutic use; D000077206:Gabapentin; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology; D007099:Imipramine / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use; D051379:Mice; D000078764:Milnacipran; D009020:Morphine / Q000627:therapeutic use; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D017374:Paroxetine / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D002220:Carbamazepine; D003509:Cyclohexanecarboxylic Acids; D003521:Cyclopropanes; D000077206:Gabapentin; D007099:Imipramine; D007213:Indomethacin; D008801:Mexiletine; D000078764:Milnacipran; D009020:Morphine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid